Juvenile Idiopathic Arthritis
📧 Sign up to get email alerts when something new happens for Juvenile Idiopathic Arthritis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-24EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) for multiple inflammatory diseases including rheumatoid arthritis and Crohn's disease.
-
EMA approval · 2026-08-21EMA Authorised: Tuyory — Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)
EMA authorised Tuyory from Chemical Works of Gedeon Richter Plc. for multiple indications including rheumatoid arthritis, juvenile arthritis…
-
EMA approval · 2026-08-19EMA Authorised: Tyenne (tocilizumab) — Fresenius Kabi Deutschland GmbH
Tyenne (tocilizumab) has been authorised by the EMA for multiple indications including rheumatoid arthritis, cytokine release syndrome, juve…
-
EMA approval · 2026-08-18EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
Amgevita (adalimumab) by Amgen Europe B.V. has been authorised by the EMA for multiple inflammatory diseases including arthritis, psoriatic …
-
EMA approval · 2026-08-13EMA Authorised: RoActemra (tocilizumab) — Roche Registration GmbH
RoActemra (tocilizumab) has been authorised by the European Medicines Agency for multiple indications including rheumatoid arthritis, juveni…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-08-06EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) from Fresenius Kabi Deutschland for multiple inflammatory diseases including rheuma…
-
EMA approval · 2026-08-05EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
EMA authorises Humira (adalimumab) for multiple inflammatory diseases across indications, confirming market authorization.
-
EMA approval · 2026-07-21EMA Authorised: Gobivaz (golimumab) — Advanz Pharma Limited
Authorised status for Gobivaz (golimumab) by Advanz Pharma Limited for multiple inflammatory diseases, expanding label in Europe.
-
EMA approval · 2026-07-17EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EU authorization of Hukyndra (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including rheumatoid arthritis and inf…
-
EMA approval · 2026-07-13EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
Authorised status for Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory and autoimmune diseases.
-
EMA approval · 2026-07-13EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) for multiple inflammatory diseases, expanding the portfolio under Fresenius Kabi De…
-
EMA approval · 2026-07-01EMA Authorised: Gotenfia (golimumab) — Stada Arzneimittel AG
European Medicines Agency authorised Gotenfia (golimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including various form…
-
EMA approval · 2026-06-15EMA Authorised: Tuyory — Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)
Tuyory has been authorised by the EMA for multiple indications including rheumatoid arthritis, juvenile arthritis, cytokine release syndrome…
-
EMA approval · 2026-06-12EMA Authorised: Fubelv — Biosimilar Collaborations Ireland Limited
EMA has authorised Fubelv as a biosimilar, with indications across various inflammatory arthritis and psoriasis conditions.
-
EMA approval · 2026-06-05EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
The EMA has authorised Idacio (adalimumab) by Fresenius Kabi Deutschland GmbH for multiple inflammatory diseases, marking a new approved pro…
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: OLE Study With Filgotinib in JIA [Phase 3]
Phase 3 ongoing trial update for filgotinib in juvenile idiopathic arthritis (JIA).
-
EMA approval · 2026-04-23EMA Authorised: Taltz (ixekizumab) — Eli Lilly and Company (Ireland) Limited
EMA authorised Taltz (ixekizumab) from Eli Lilly for psoriasis, psoriatic arthritis, axial spondyloarthritis, and juvenile idiopathic arthri…
-
EMA approval · 2026-04-23EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.
EMA has authorised Amgevita (adalimumab) by Amgen Europe B.V., a biosimilar of adalimumab, for multiple inflammatory diseases including rheu…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: JIA Toolbox Feasibility Study [NA]
Feasibility study evaluating a JIA toolbox is currently listed as active but not recruiting, sponsored by Sheffield Children's NHS Foundatio…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis [Phase 3]
This Phase 3 trial is evaluating sequential medications after TNF inhibitor failure in polyarticular juvenile idiopathic arthritis. The stud…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases [Phase 4]
Phase 4 clinical trial assessing safety and immunogenicity of the live attenuated tetravalent Butantan-Dengue vaccine in autoimmune rheumati…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants [Phase 3]
A long-term extension study of guselkumab in pediatric participants with Crohn's disease, ulcerative colitis, psoriatic arthritis, and juven…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Pain in Inflammatory Joint Diseases
The clinical trial update reports that a study on pain in inflammatory joint diseases is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Host-microbiota-environment Interactions
This clinical trial update reports that the host-microbiota-environment interactions study (NCT05176795) involving juvenile idiopathic arthr…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis [Phase 2]
This Phase 2 clinical trial is evaluating the pharmacokinetics, efficacy, and safety of olokizumab in patients with Juvenile idiopathic arth…